Cargando…
Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory
Genotyping epidermal growth factor receptor (EGFR) gene in patients with advanced non-small cell lung cancers (NSCLC) is essential for identifying those patients who may benefit from targeted therapies. Systemically evaluating EGFR mutation detection rates of different methods currently used in clin...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262202/ https://www.ncbi.nlm.nih.gov/pubmed/34257561 http://dx.doi.org/10.3389/pore.2021.602726 |
_version_ | 1783719144605089792 |
---|---|
author | Mao, Linlin Zhao, Weiwei Li, Xiaoxia Zhang, Shangfei Zhou, Changhong Zhou, Danyan Ou, Xiaohua Xu, Yanyan Tang, Yuanxiao Ou, Xiaoyong Hu, Changming Ding, Xiangdong Luo, Pifu Yu, Shihui |
author_facet | Mao, Linlin Zhao, Weiwei Li, Xiaoxia Zhang, Shangfei Zhou, Changhong Zhou, Danyan Ou, Xiaohua Xu, Yanyan Tang, Yuanxiao Ou, Xiaoyong Hu, Changming Ding, Xiangdong Luo, Pifu Yu, Shihui |
author_sort | Mao, Linlin |
collection | PubMed |
description | Genotyping epidermal growth factor receptor (EGFR) gene in patients with advanced non-small cell lung cancers (NSCLC) is essential for identifying those patients who may benefit from targeted therapies. Systemically evaluating EGFR mutation detection rates of different methods currently used in clinical setting will provide valuable information to clinicians and laboratory scientists who take care of NSCLC patients. This study retrospectively reviewed the EGFR data obtained in our laboratory in last 10 years. A total of 21,324 NSCLC cases successfully underwent EGFR genotyping for clinical therapeutic purpose, including 5,244 cases tested by Sanger sequencing, 13,329 cases tested by real-time PCR, and 2,751 tested by next-generation sequencing (NGS). The average EGFR mutation rate was 45.1%, with 40.3% identified by Sanger sequencing, 46.5% by real-time PCR and 47.5% by NGS. Of these cases with EGFR mutations identified, 93.3% of them harbored a single EGFR mutation (92.1% with 19del or L858R, and 7.9% with uncommon mutations) and 6.7% harbored complex EGFR mutations. Of the 72 distinct EGFR variants identified in this study, 15 of them (single or complex EGFR mutations) were newly identified in NSCLC. For these cases with EGFR mutations tested by NGS, 65.3% of them also carried tumor-related variants in some non-EGFR genes and about one third of them were considered candidates of targeted drugs. NGS method showed advantages over Sanger sequencing and real-time PCR not only by providing the highest mutation detection rate of EGFR but also by identifying actionable non-EGFR mutations with targeted drugs in clinical setting. |
format | Online Article Text |
id | pubmed-8262202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82622022021-07-12 Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory Mao, Linlin Zhao, Weiwei Li, Xiaoxia Zhang, Shangfei Zhou, Changhong Zhou, Danyan Ou, Xiaohua Xu, Yanyan Tang, Yuanxiao Ou, Xiaoyong Hu, Changming Ding, Xiangdong Luo, Pifu Yu, Shihui Pathol Oncol Res Society Journal Archive Genotyping epidermal growth factor receptor (EGFR) gene in patients with advanced non-small cell lung cancers (NSCLC) is essential for identifying those patients who may benefit from targeted therapies. Systemically evaluating EGFR mutation detection rates of different methods currently used in clinical setting will provide valuable information to clinicians and laboratory scientists who take care of NSCLC patients. This study retrospectively reviewed the EGFR data obtained in our laboratory in last 10 years. A total of 21,324 NSCLC cases successfully underwent EGFR genotyping for clinical therapeutic purpose, including 5,244 cases tested by Sanger sequencing, 13,329 cases tested by real-time PCR, and 2,751 tested by next-generation sequencing (NGS). The average EGFR mutation rate was 45.1%, with 40.3% identified by Sanger sequencing, 46.5% by real-time PCR and 47.5% by NGS. Of these cases with EGFR mutations identified, 93.3% of them harbored a single EGFR mutation (92.1% with 19del or L858R, and 7.9% with uncommon mutations) and 6.7% harbored complex EGFR mutations. Of the 72 distinct EGFR variants identified in this study, 15 of them (single or complex EGFR mutations) were newly identified in NSCLC. For these cases with EGFR mutations tested by NGS, 65.3% of them also carried tumor-related variants in some non-EGFR genes and about one third of them were considered candidates of targeted drugs. NGS method showed advantages over Sanger sequencing and real-time PCR not only by providing the highest mutation detection rate of EGFR but also by identifying actionable non-EGFR mutations with targeted drugs in clinical setting. Frontiers Media S.A. 2021-04-07 /pmc/articles/PMC8262202/ /pubmed/34257561 http://dx.doi.org/10.3389/pore.2021.602726 Text en Copyright © 2021 Mao, Zhao, Li, Zhang, Zhou, Zhou, Ou, Xu, Tang, Ou, Hu, Ding, Luo and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Society Journal Archive Mao, Linlin Zhao, Weiwei Li, Xiaoxia Zhang, Shangfei Zhou, Changhong Zhou, Danyan Ou, Xiaohua Xu, Yanyan Tang, Yuanxiao Ou, Xiaoyong Hu, Changming Ding, Xiangdong Luo, Pifu Yu, Shihui Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory |
title | Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory |
title_full | Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory |
title_fullStr | Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory |
title_full_unstemmed | Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory |
title_short | Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory |
title_sort | mutation spectrum of egfr from 21,324 chinese patients with non-small cell lung cancer (nsclc) successfully tested by multiple methods in a cap-accredited laboratory |
topic | Society Journal Archive |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262202/ https://www.ncbi.nlm.nih.gov/pubmed/34257561 http://dx.doi.org/10.3389/pore.2021.602726 |
work_keys_str_mv | AT maolinlin mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory AT zhaoweiwei mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory AT lixiaoxia mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory AT zhangshangfei mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory AT zhouchanghong mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory AT zhoudanyan mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory AT ouxiaohua mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory AT xuyanyan mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory AT tangyuanxiao mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory AT ouxiaoyong mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory AT huchangming mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory AT dingxiangdong mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory AT luopifu mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory AT yushihui mutationspectrumofegfrfrom21324chinesepatientswithnonsmallcelllungcancernsclcsuccessfullytestedbymultiplemethodsinacapaccreditedlaboratory |